MeSH term
Frequency | Condition_Probility | Aged | 5 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Female | 17 | 0.0 |
Humans | 59 | 0.0 |
English Abstract | 2 | 0.0 |
*Membrane Proteins | 2 | 0.0 |
Animals | 34 | 0.0 |
COS Cells | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 39 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 24 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Mice | 19 | 0.0 |
Mice, Nude | 7 | 0.0 |
Transplantation, Heterologous | 5 | 0.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Male | 20 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Mutation | 2 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Protein-Lysine 6-Oxidase/*genetics | 4 | 44.0 |
Chromosomes, Human, Pair 5/*genetics | 3 | 3.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Molecular Sequence Data | 7 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Tumor Cells, Cultured | 11 | 0.0 |
Adult | 7 | 0.0 |
Middle Aged | 5 | 0.0 |
Rats | 4 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Binding Sites | 3 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Databases, Factual | 2 | 0.0 |
Exons | 2 | 0.0 |
Introns | 3 | 0.0 |
Models, Genetic | 2 | 0.0 |
*Gene Expression | 3 | 0.0 |
Pregnancy | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Amino Acid Oxidoreductases/*genetics | 2 | 12.0 |
Multigene Family | 2 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
Cyclooxygenase Inhibitors/pharmacology/therapeutic use | 2 | 50.0 |
Lipoxygenase/*physiology | 2 | 66.0 |
Up-Regulation | 2 | 0.0 |
Protein-Lysine 6-Oxidase/genetics/*metabolism | 2 | 100.0 |
Immunohistochemistry | 2 | 0.0 |
Phenotype | 3 | 0.0 |
Protein-Lysine 6-Oxidase/*biosynthesis | 2 | 100.0 |
3T3 Cells | 2 | 0.0 |
Cyclooxygenase Inhibitors/pharmacology | 2 | 2.0 |
Lipoxygenase Inhibitors/pharmacology | 2 | 12.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
In Vitro | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
Cell Line | 5 | 0.0 |
Cell Movement | 2 | 0.0 |
Melanoma/*pathology | 2 | 3.0 |
Transfection | 5 | 0.0 |
Base Sequence | 4 | 0.0 |
Reference Values | 2 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Clinical Trials | 2 | 0.0 |
Melphalan/*pharmacokinetics/therapeutic use | 2 | 100.0 |
Haplotypes | 2 | 0.0 |
Comparative Study | 5 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Amine Oxidase (Copper-Containing)/metabolism | 2 | 10.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Arachidonate 12-Lipoxygenase/*metabolism | 2 | 50.0 |
Neoplasm Transplantation | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
